Hennion & Walsh Asset Management, Inc. Tg Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 101,369 shares of TGTX stock, worth $2.25 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
101,369
Previous 184,815
45.15%
Holding current value
$2.25 Million
Previous $2.81 Million
35.86%
% of portfolio
0.1%
Previous 0.15%
Shares
14 transactions
Others Institutions Holding TGTX
# of Institutions
288Shares Held
91.8MCall Options Held
1.9MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA13.7MShares$304 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$253 Million0.0% of portfolio
-
State Street Corp Boston, MA6.7MShares$149 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.65MShares$81 Million6.57% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.24MShares$72.1 Million0.07% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $3.23B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...